Wakefern Food Corp. and Bonum Health(TM), LLC (a TRxADE HEALTH Company) Ink a Telemedicine Services Deal

TAMPA, FL / ACCESSWIRE / September 20, 2022 / TRxADE HEALTH, INC. (NASDAQ:MEDS)(“TRxADE” or the “Company”) an integrated drug procurement, delivery, and healthcare platform, today announced that Bonum Health, a Digital Healthcare business subsidiary, has signed a Telemedicine Services Distribution Deal with Wakefern Food Corp., to deploy telemedicine services throughout ShopRite pharmacy-led locations in New Jersey, New York, Pennsylvania, Connecticut, and Maryland.

Bonum Health will provide affordable telemedicine services and prescription discount savings to ShopRite customers by offering Bonum Health’s signature Mobile Health Services application and prescriber program, staffed by over 650+ Board-Certified Medical Providers. The service, which allows customers to connect virtually with doctors and healthcare providers, to get the care they need, also provides access to prescription discount savings through the innovative Bonum Health telemedicine application, which can be downloaded from both Google Play and Apple App stores.

Dr. Shafaat Pirani, PharmD, BCGP, Chief Clinical and Compliance Officer for TRxADE states, “We are ecstatic about working strategically with Wakefern Food Corp., the retailer-owned supermarket cooperative, to offer deep discounts for telemedicine services in the tristate area and neighboring states. The relationship speaks to the ethos of what Bonum Health is all about – improving access to healthcare services for the growing uninsured and under-insured population. Today, it is more important than ever to make sure people have affordable and accessible healthcare.”

“This partnership will highlight synergies across both brands, such as a preferred Veterinary plan where customers will be able to access Tele-Veterinary services in select markets and receive their pet prescriptions and over-the-counter drugs. These are precisely the value-based opportunities we believe customers are looking for today,” Dr. Pirani added.

“Telemedicine provides a convenient and user-friendly way for people to access health care services. With providers and patients looking to break down physical and scheduling barriers to delivering and receiving care, telehealth offers a seamless, accessible health care solution. We are excited to introduce Bonum Health’s signature Mobile Health Services application to help our customers achieve their health and wellness goals,” said Joe Montoto, RPh, Pharmacy Business Development Manager at Wakefern Food Corp.

“We are pleased to announce this collaboration with Wakefern Food Corp and Bonum Health, as it demonstrates our commitment to expanding our affordable and convenient telemedicine services with our supermarket partners. We look forward to building on this opportunity and creating innovative, game-changing health care solutions,” said Suren Ajjarapu, Chairman and Chief Executive Officer of TRxADE.

About Wakefern Food Corp

From a small, local cooperative that began with eight grocery store owners, Wakefern Food Corp. has grown into the largest retailer-owned cooperative in the United States. Founded in 1946, the cooperative includes 47 member families who today independently own and operate hundreds of supermarkets under the ShopRite, Price Rite Marketplace, The Fresh Grocer, Dearborn Market, Gourmet Garage, and Fairway Market banners in New Jersey, New York, Connecticut, Pennsylvania, Maryland, Delaware, Massachusetts, New Hampshire and Rhode Island. For more information, please visit www.wakefern.com.

About ShopRite

ShopRite is the registered trademark of Wakefern Food Corp., a retailer-owned cooperative based in Keasbey, NJ, and the largest supermarket cooperative in the United States. With hundreds of supermarkets located throughout New Jersey, New York, Pennsylvania, Connecticut, Delaware and Maryland, ShopRite serves millions of customers each week. Through its ShopRite Partners In Caring program, ShopRite is dedicated to fighting hunger in the communities it serves. Since the program began in 1999, ShopRite Partners In Caring has donated nearly $62 million to food banks that support more than 2,200 worthy charities. As a title sponsor of the ShopRite LPGA Classic Presented by Acer, ShopRite has donated more than $35 million to local organizations, hospitals and community groups. For more information, please visit www.shoprite.com.

About TRxADE HEALTH, INC.

TRxADE HEALTH (NASDAQ: MEDS) is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey, and patient engagement in the U.S. The Company operates the TRxADE drug procurement marketplace serving a total of approximately 13,475 members nationwide, fostering price transparency, and under the Bonum Health brand, offering patient-centric telehealth services. For info on TRxADE HEALTH, please visit the Company’s IR website at investors.trxadegroup.com.

Forward-Looking Statements

This press release may contain forward-looking statements, including information about management’s view of TRxADE’s future expectations, plans, and prospects, within the meaning of the federal securities laws, including the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event, or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other factors, which may cause the results of TRxADE, its divisions, and concepts to be materially different from those expressed or implied in such statements. These risks include risks relating to agreements with third parties, including Wakefern Food Corp., Coborn’s and Galt Pharmaceuticals; our ability to raise funding in the future and the availability and terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; the planned benefits, expected users of, and projected revenues of our venture with Exchange Health; amounts we owe and may owe to Exchange Health in connection with the arrangement with Exchange Health; security interests under certain of our credit arrangements; the fact that we are exploring strategic alternatives for our Bonum Health, Inc. subsidiary; our operations not being profitable; the commercial viability of new business lines, applications, products and technologies, and the costs of such items; the Company’s stock repurchase program; the adoption of the Company’s product offerings; claims relating to alleged violations of intellectual property rights of others; our ability to monetize our technological solutions; technical problems with our websites, apps and products; risks relating to implementing our acquisition strategies; challenges to the pharmaceutical supply chain posted by the COVID-19 pandemic and related matters; our ability to manage our growth; negative effects on our operations associated with the opioid pain medication health crisis; regulatory and licensing requirement risks; risks related to changes in the U.S. healthcare environment; the status of our information systems, facilities and distribution networks; risks associated with the operations of our more established competitors; regulatory changes; new competitors which may have more resources than we do; increases in direct to consumer sales of drugs; healthcare fraud; COVID-19, governmental responses thereto, economic downturns and increased inflation and interest rates, and possible recessions caused thereby; changes in laws or regulations relating to our operations; privacy laws; system errors; dependence on current management; our growth strategy; dilution which may be caused by future offerings; our ability to maintain the listing of our common stock on the Nasdaq Capital Market, including our current non-compliance with Nasdaq’s continued listing standards; increased inflation, increases in interest rates and supply chain issues caused by among other things, recessions and global conflicts; and others that are included from time to time in filings made by TRxADE with the Securities and Exchange Commission, including, but not limited to, in the “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which it has filed, and files from time to time, with the U.S. Securities and Exchange Commission (SEC), and more particularly in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, and our Annual Report on Form 10-K for the year ended December 31, 2021. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on TRxADE’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. TRxADE cannot guarantee future results, levels of activity, performance, or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions, or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Media Contact:

IR@trxade.com
(800) 261-0281

SOURCE: TRxADE HEALTH, INC.

Bonum Health(TM) (TRxADE HEALTH Company) Launches Veterinary Telemedicine Services

TAMPA, FL / ACCESSWIRE / May 19, 2022/ TRxADE HEALTH, INC. (NASDAQ:MEDS) an integrated drug procurement, delivery, and healthcare platform, today announced that Bonum Health, a Digital Healthcare business subsidiary, has launched Tele-Veterinary services for pets.

The company, which offers nationwide telemedicine services for humans, will now add a digital veterinary clinic, staffed by veterinarians to its platform and will begin catering to cats and dogs in limited markets. Ashton Maaraba, President of Bonum Health states, “We are excited to add Tele-Vet to our fast-growing telemedicine platform. Over the years, we found significant demand in this space, and as we studied the benefit and growth potential of this new model, it became evident to us that we needed to pursue it. We plan on launching in limited markets as this provides us the opportunity to scale and expand our care services beyond cats and dogs, while studying the required capacity to keep up with demand. We believe that our vet clinic has the potential for significant growth.” Maaraba also mentioned, “The company maintains a strong commitment to its retail members that are investing in their own pet programs, and that Bonum Health Tele-Vet complements a shared vision by delivering to consumer households more viable pet health options. We are pleased to have Bonum Health decide to enter into this space and add greater value to its household subscriber and we are excited to advance this latest innovation for its exiting patient base,” said Suren Ajjarapu, Chairman and Chief Executive Officer of TRxADE.

According to the American Veterinary Medical Association’s (AVMA) 2017-2018 U.S. Pet Ownership & Demographics Sourcebook, approximately 38.4% of American households own at least one dog, and 25.4% own at minimum one cat. According to a January 2022 report by Grand View Research, in 2021, the global Tele-Vet market was worth approximately $119.6 million, and is expected to grow to at a 17.6% compounded annual growth rate through 2030.

Company officials revealed its first three markets, Illinois, New York, and Pennsylvania and with the number of vets that are undergoing its stringent credentialing process, it aims to offer services across more states within the upcoming months. The company pointed out that it has adopted the requisite protocols to ensure full compliance with AVMA guidelines in the states in which it serves pets.

About TRxADE HEALTH, INC.

TRxADE HEALTH (NASDAQ: MEDS) is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. The Company operates the TRxADE drug procurement marketplace serving a total of 13,475 members nationwide, fostering price transparency and under the Bonum Health brand, offering patient centric telehealth services. For info on TRxADE HEALTH, please visit the Company’s IR website at investors.trxadegroup.com.

Forward-Looking Statements

This press release may contain forward-looking statements, including information about management’s view of TRxADE’s future expectations, plans and prospects, within the meaning of the federal securities laws, including the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of TRxADE, its divisions and concepts to be materially different than those expressed or implied in such statements. These risks include risks relating to agreements with third parties, including Coborn’s; the planned benefits, expected users of, and projected revenues of our venture with Exchange Health; amounts we owe and may owe to Exchange Health in connection with the arrangement with Exchange Health; security interests under certain of our credit arrangements; the fact that we are exploring strategic alternatives for our Bonum Health, Inc. subsidiary; our operations not being profitable; the commercial viability of new business lines, applications, products and technologies, and the costs of such items; the Company’s stock repurchase program; the adoption of the Company’s product offerings; claims relating to alleged violations of intellectual property rights of others; our ability to monetize our technological solutions; technical problems with our websites, apps and products; risks relating to implementing our acquisition strategies; challenges to the pharmaceutical supply chain posted by the COVID-19 pandemic and related matters; our ability to manage our growth; negative effects on our operations associated with the opioid pain medication health crisis; regulatory and licensing requirement risks; risks related to changes in the U.S. healthcare environment; the status of our information systems, facilities and distribution networks; risks associated with the operations of our more established competitors; regulatory changes; new competitors which may have more resources than we do; increases in direct to consumer sales of drugs; healthcare fraud; COVID-19, governmental responses thereto, economic downturns and increased inflation and possible recessions caused thereby; changes in laws or regulations relating to our operations; privacy laws; system errors; dependence on current management; our growth strategy; dilution which may be caused by future offerings; our ability to raise funding in the future, as and if needed, and the terms of such funding; increased inflation; and others that are included from time to time in filings made by TRxADE with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which it has filed, and files from time to time, with the U.S. Securities and Exchange Commission (SEC), and more particularly in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 and our Annual Report on Form 10-K for the year ended December 31, 2021. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on TRxADE’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. TRxADE cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Media Contact:

IR@trxade.com
(800) 261-0281

SOURCE: TRxADE HEALTH, Inc.

https://finance.yahoo.com/news/bonum-health-tm-trxade-health-123000472.html

Bonum Health Announces Prescription Savings Partnership with SingleCare

Source: Trxade Group, Inc.

TAMPA, FL, Oct. 13, 2020 (GLOBE NEWSWIRE) — Trxade Group Inc. (NASDAQ: MEDS), an integrated drug procurement, delivery and healthcare platform, today announced that its Bonum Health subsidiary has partnered with SingleCare, the prescription savings service, to enhance Bonum Health’s enterprise telehealth solutions with prescription discounts powered by SingleCare. The enterprise service will be offered to national, regional and local pharmacies to promote the benefit to uninsured patients and underserved communities.

The increasing cost of healthcare has been exacerbated by the economic pressures of COVID-19, especially for the millions of recently unemployed across America. Bonum Health enables convenient access to affordable care with its clinical technology platform and telehealth solutions that offer virtual medical and provider services at deeply discounted rates. Through these telehealth solutions, an entire household can receive a virtual consultation by board-certified medical doctors, anywhere, at any time.

SingleCare is a free prescription savings service that is providing millions of consumers across America with consistently low prices to improve access and adherence to medication. SingleCare is able to save customers up to 80% on their prescriptions. Most people don’t realize they can shop for better prices on their medications. SingleCare provides consistently low prices, and it can often be cheaper than a copay – so whether or not you have insurance, it’s always worth checking.

Bonum Health President, Ashton Maaraba, credits the team’s innovative thinking and complementary community-driven strategy. “The Bonum Health and SingleCare teams understand the importance of integrating and sustaining an affordable healthcare solution at pharmacy point-of-care. We are veterans in promoting quality healthcare service-driven programs at the pharmacy level and differentiate by providing transparent and affordable benefits that pharmacy partners and their patient community can trust, “ said Maaraba.

“We’re pleased to partner with Bonum Health as it allows us to expand our pharmacy distribution channels where SingleCare is offered, and help more consumers with access and adherence to affordable medication,” said John Zevzavadijan, President of Enterprise Platform Services at SingleCare.

About SingleCare

SingleCare®️ is a free prescription savings service that provides consistently low prices to improve access and adherence to medication. It handles hundreds of thousands of prescriptions per day and is helping millions of people across the U.S. save a significant amount of money on their prescriptions. Through a combination of innovative technology and direct contracts with pharmacies, SingleCare allows consumers to access prescription savings at pharmacies near them via the mobile app or discount cards available on SingleCare.com. SingleCare partners with the country’s leading pharmacy companies covering 35,000 pharmacies nationwide. SingleCare is headquartered in Boston with offices in New York City, greater Philadelphia and West Palm Beach, Fla. For more information, visit singlecare.com or download SingleCare on iOS or Android.

About Trxade Group, Inc.

Headquartered in Tampa, Florida, Trxade Group, Inc. (Nasdaq: MEDS) is an integrated drug procurement, delivery and healthcare platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. Trxade Group operates across all 50 states with the central mission of making healthcare services affordable and accessible. Founded in 2010, Trxade Group is comprised of three synergistic operating platforms; (1) the Trxade B2B trading platform with around 11,800 registered pharmacies, (2) Integra Pharma Solutions, Trxade Group’s virtual wholesale division, and (3) the Bonum Health platform offering affordable telehealth services. For additional information, please visit us at www.trxade.com or at www.bonumhealth.com.

 

Trxade Group Inc Announces Launch of Bonum Health+ B2B Platform

Bonum Health+ Bundles Telehealth, a COVID-19 Risk Assessment Tool and a PPE Purchasing Tool, through a Secure Mobile Dashboard for Corporate Clients

TAMPA, FL, Aug. 11, 2020 (GLOBE NEWSWIRE) — Trxade Group, Inc. (NASDAQ: MEDS), an integrated drug procurement, delivery and healthcare platform, today announced that its Bonum Health subsidiary has launched a first-of-its-kind Business-to-Business (B2B) platform called Bonum Health+, which bundles telehealth, a COVID-19 risk assessment tool and a Personal Protective Equipment (PPE) purchasing tool, through a secure mobile dashboard for corporate clients.

The new B2B platform eases pressure on employees who are required to report any relevant health issues daily, centralizing communication and contact tracing to deliver risk scores. This allows employers to monitor employee COVID-19 risk profiles and streamlines the ordering of new PPE as needed. An integrated artificial intelligence (AI) tool offers health recommendations and connects employees with board certified physicians, as needed.

“I am proud of the entire team at Bonum Health, a Trxade Group Company, for their efforts in launching this innovative new service,” said Ashton Maaraba, President of Bonum Health. “This platform resolves a fundamental trust problem impacting employer’s safety and security policies, allowing companies to more effectively combat COVID-19 concerns in the workplace.”

“Looking forward, we plan to continue to expand the breadth of services offered by Bonum Health, including adding a digital health hub with next-generation prescription concierge services. We believe that we are well positioned to execute upon the immense opportunity facing us today, supporting critical public health efforts nationwide,” concluded Maaraba.

About Trxade Group, Inc.

Headquartered in Tampa, Florida, Trxade Group, Inc. (Nasdaq: MEDS) is an integrated drug procurement, delivery and healthcare platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. Trxade Group operates across all 50 states with the central mission of making healthcare services affordable and accessible. Founded in 2010, Trxade Group is comprised of four synergistic operating platforms; (1) the Trxade B2B trading platform with 11,725 registered pharmacies, (2) Integra Pharma Solutions, Trxade Group’s virtual wholesale division, (3) the Bonum Health platform offering affordable telehealth services; and (4) the DelivMeds app, which coordinates a nationwide distribution network through independent pharmacies or mail order delivery. For additional information, please visit us at www.trxade.comwww.delivmeds.com, and www.bonumhealth.com.

Bonum Health Announces New Prescription Education Resources via Telehealth App

Trxade Group, Inc. (NASDAQ: MEDS) an integrated drug procurement, delivery and healthcare platform announces new app feature within it’s Telehealth Application, Bonum Health. New Patient Prescription Education development includes a new searchable medication appendix to providing patients with visual identification and written information regarding any current medication or prescription.

Within each patient’s profile, the resource features continue to evolve to better educate patients on their health. The patient can query a drug search within the app to identify pertinent information such as food and drug interactions and more regarding the therapies they have been prescribed. This feature not only intends to improve health literacy of their prescribed therapies but also improve overall health outcomes. Medications and formulations of prescriptions are listed along with a visual medication identifier guide for typical shape and color.

As a supplement to additional medication questions, the application allows patients to research further by allowing for web searches as well as social media postings, inquiries and discussions. The aim of our Telehealth service is to assist every patient by providing well trained physicians, patient education, and a wealth of resources to ensure good health and compliance.

####

About Trxade Group, Inc. Headquartered in Tampa, Florida, Trxade Group, Inc. (Nasdaq: MEDS) is an integrated drug procurement, delivery and healthcare platform that enables price transparency and increased profit margins to healthcare buyers and sellers of pharmaceuticals. Founded in 2010, Trxade Group is comprised of three synergistic operating platforms; the Trxade B2B trading platform with 11,900 registered pharmacies, licensed virtual Wholesale and Mail Order Pharmacy delivery capabilities using DelivMeds app. For additional information, please visit us at http://www.trxade.com http://www.delivmeds.com, and http://www.bonumhealth.com.